Standout Papers
- Esophageal Cancer (2003)
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus (2018)
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023)
Immediate Impact
2 by Nobel laureates 14 from Science/Nature 68 standout
Citing Papers
Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
Oesophageal cancer
2024 Standout
Works of Peter C. Enzinger being referenced
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2023 Standout
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
2018 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Peter C. Enzinger | 3380 | 4125 | 3301 | 145 | 8.2k | |
| Tarek Sahmoud | 4830 | 5060 | 3016 | 129 | 11.1k | |
| David Malka | 2497 | 5343 | 3968 | 228 | 9.0k | |
| Rosine Guimbaud | 2452 | 7517 | 2226 | 177 | 9.3k | |
| Maria Di Bartolomeo | 2316 | 4586 | 1385 | 247 | 6.3k | |
| Mark M. Zalupski | 2352 | 4824 | 1591 | 196 | 6.7k | |
| Peter Harper | 3134 | 4613 | 1834 | 139 | 7.6k | |
| Federica Perrone | 2683 | 3566 | 1976 | 234 | 7.8k | |
| Thomas Aparicio | 1991 | 3417 | 1711 | 242 | 6.2k | |
| Todd W. Bauer | 2892 | 3992 | 3600 | 179 | 6.9k | |
| Young Suk Park | 2223 | 3887 | 1883 | 223 | 6.2k |
All Works
Loading papers...